![Consensus on diagnosis and management of Cushing's disease: a guideline update - The Lancet Diabetes & Endocrinology Consensus on diagnosis and management of Cushing's disease: a guideline update - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/8aa621fa-16a6-4a2e-9964-1715eadef228/gr1_lrg.jpg)
Consensus on diagnosis and management of Cushing's disease: a guideline update - The Lancet Diabetes & Endocrinology
![Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis | Drug and Therapeutics Bulletin Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis | Drug and Therapeutics Bulletin](https://dtb.bmj.com/content/dtb/59/7/107/F1.large.jpg)
Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis | Drug and Therapeutics Bulletin
![Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis - - 2002 - Journal of Bone and Mineral Research - Wiley Online Library Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis - - 2002 - Journal of Bone and Mineral Research - Wiley Online Library](https://asbmr.onlinelibrary.wiley.com/cms/asset/5933a889-d1fd-4666-99e6-47ba66bd680e/mtbl002.gif)
Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis - - 2002 - Journal of Bone and Mineral Research - Wiley Online Library
![Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis - - 2002 - Journal of Bone and Mineral Research - Wiley Online Library Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis - - 2002 - Journal of Bone and Mineral Research - Wiley Online Library](https://asbmr.onlinelibrary.wiley.com/cms/asset/63d09608-1b56-4f95-ae7a-f5c63a1c2641/mtbl001.gif)
Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis - - 2002 - Journal of Bone and Mineral Research - Wiley Online Library
![Active Learning Template - Alendronate - ACTIVE LEARNING TEMPLATES THERAPEUTIC PROCEDURE A - Studocu Active Learning Template - Alendronate - ACTIVE LEARNING TEMPLATES THERAPEUTIC PROCEDURE A - Studocu](https://d20ohkaloyme4g.cloudfront.net/img/document_thumbnails/6218b9bde5bb6594adbbc0a5d1d2f863/thumb_1200_1553.png)
Active Learning Template - Alendronate - ACTIVE LEARNING TEMPLATES THERAPEUTIC PROCEDURE A - Studocu
![Alendronate Drug Card - Drug Card Template Student Name: Classification : Biphosphonate Generic - Studocu Alendronate Drug Card - Drug Card Template Student Name: Classification : Biphosphonate Generic - Studocu](https://d20ohkaloyme4g.cloudfront.net/img/document_thumbnails/164926fbce77d3f8e473c3d5888e1c1d/thumb_1200_1553.png)
Alendronate Drug Card - Drug Card Template Student Name: Classification : Biphosphonate Generic - Studocu
![Alendronate - drug card - Week # 6 Generic Name Alendronate Brand Name: Binosto Therapeutic Class - Studocu Alendronate - drug card - Week # 6 Generic Name Alendronate Brand Name: Binosto Therapeutic Class - Studocu](https://d20ohkaloyme4g.cloudfront.net/img/document_thumbnails/00e624e6987413cb2125f77f35e48d69/thumb_1200_1553.png)
Alendronate - drug card - Week # 6 Generic Name Alendronate Brand Name: Binosto Therapeutic Class - Studocu
![Quantitative lateral flow immunoassay for rapid detection of procollagen type I N-terminal propeptide in the monitoring of osteoporosis treatment - ScienceDirect Quantitative lateral flow immunoassay for rapid detection of procollagen type I N-terminal propeptide in the monitoring of osteoporosis treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0003267022012661-ga1.jpg)
Quantitative lateral flow immunoassay for rapid detection of procollagen type I N-terminal propeptide in the monitoring of osteoporosis treatment - ScienceDirect
![Bisphosphonates – Alendronate - Assessment Technologies Institute: Pharmacology Made Easy 4 1 Drug - Studocu Bisphosphonates – Alendronate - Assessment Technologies Institute: Pharmacology Made Easy 4 1 Drug - Studocu](https://d20ohkaloyme4g.cloudfront.net/img/document_thumbnails/7b045b2d0198cd13fa3d7fe3cec50d41/thumb_1200_1535.png)
Bisphosphonates – Alendronate - Assessment Technologies Institute: Pharmacology Made Easy 4 1 Drug - Studocu
![Monitoring Alendronate Therapy for Osteoporosis - De castro machado - 1999 - Journal of Bone and Mineral Research - Wiley Online Library Monitoring Alendronate Therapy for Osteoporosis - De castro machado - 1999 - Journal of Bone and Mineral Research - Wiley Online Library](https://asbmr.onlinelibrary.wiley.com/cms/asset/cbd47fa4-dea1-42d1-b1fc-87a5d7e013ba/mtbl001.gif)
Monitoring Alendronate Therapy for Osteoporosis - De castro machado - 1999 - Journal of Bone and Mineral Research - Wiley Online Library
![Alendronate (Fosamax) - Ch. 48 Biphosphonates Inhibits resorption of bone by inhibiting osteoclast - Studocu Alendronate (Fosamax) - Ch. 48 Biphosphonates Inhibits resorption of bone by inhibiting osteoclast - Studocu](https://d20ohkaloyme4g.cloudfront.net/img/document_thumbnails/dc139fa7f473cadad990d4c15fd5b1a8/thumb_1200_1553.png)
Alendronate (Fosamax) - Ch. 48 Biphosphonates Inhibits resorption of bone by inhibiting osteoclast - Studocu
![Osteoporosis Workup: Approach Considerations, Laboratory Studies, Biochemical Markers of Bone Turnover Osteoporosis Workup: Approach Considerations, Laboratory Studies, Biochemical Markers of Bone Turnover](https://img.medscapestatic.com/pi/meds/ckb/41/39141tn.jpg)